arrow
K

Kelly Johnson

merck & co., inc.
H指数:18
被引数:1,319

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Healthcare resource utilization and cost of invasive pneumococcal disease, pneumonia, and acute otitis media in commercially and medicaid-insured children by risk group in the United States, 2018 to 2023

2018至2023年美国商业保险和医疗补助计划参保儿童中,按风险组划分的侵袭性肺炎球菌病、肺炎和急性中耳炎的医疗资源利用及费用

2026-09-050
OAAI
Evaluating the potential lifetime health and economic impact of PCV21, an adult-specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in adults aged ≥45 years in Spain

评估PCV21(一种成人专用21价肺炎球菌结合疫苗)对西班牙≥45岁成人侵袭性肺炎球菌疾病的潜在寿命健康和经济影响

Vaccine
IF3.5
2026-08-300
OAAI
Assessing the economic impact and healthcare resource utilization of inpatient pneumococcal disease among adults: a French national claims database study

评估成人住院肺炎球菌疾病的经济影响和医疗资源利用:一项基于法国全国医保数据库的研究

2025-02-080
OA
Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in Tennessee and Georgia, 2018-2022

2018-2022田纳西州和佐治亚州社区获得性肺炎住院成人肺炎球菌肺炎的患病率、临床严重程度和血清型分布

2024-07-1715
OAAI
Epidemiology of community-acquired pneumonia (CAP) in Europe during the COVID-19 pandemic preliminary results of PNEUMO study Europe
2023-10-270
PRE